两种中等强度他汀类药物方案治疗高脂血症的成本-效果分析

发布时间：2018-07-17 09:15

【摘要】：目的:探讨10 mg/d瑞舒伐他汀和20 mg/d阿托伐他汀治疗高脂血症(HLP)的有效性和经济性。方法:回顾性收集2015年3月-2016年2月天门市第一人民医院门诊收治的180例确诊为HLP的患者资料,根据治疗方案不同分为A、B组,各90例。A组患者给予阿托伐他汀钙片20 mg,qd;B组患者给予瑞舒伐他汀钙片10 mg,qd。两组患者疗程均为8周。比较两组患者治疗前后的血脂指标水平和治疗后的降脂疗效、血脂达标率及不良反应发生情况,并运用成本-效果分析法进行经济学评价。结果:治疗前,两组患者的血脂指标水平比较,差异均无统计学意义(P0.05)。治疗后,两组患者的总胆固醇和低密度脂蛋白胆固醇水平均明显低于治疗前,且B组水平明显低于A组,差异均有统计学意义(P0.05);B组患者的降脂总有效率(97.78%)显著高于A组(86.67%),血脂达标率(66.67%)也显著高于A组(51.11%),差异均有统计学意义(P0.05)。两组患者不良反应发生率比较,差异无统计学意义(P0.05)。A组和B组方案的成本分别为488.32、436.24元,成本-效果比分别为5.63、4.46,增量成本-效果比为-4.69,B组方案更具有成本-效果优势。敏感度分析支持成本-效果分析结果。结论:从短期疗效上分析,10 mg/d瑞舒伐他汀方案较20 mg/d阿托伐他汀方案的降脂效果更好,更具有成本-效果优势,且二者安全性相当。
[Abstract]:Objective: to investigate the efficacy and economy of 10 mg/d resuvastatin and 20 mg/d Atto vastatin in the treatment of hyperlipidemia (HLP). Methods: 180 patients with HLP were collected retrospectively from March 2015 to February 2016 in the first people's Hospital of Tianmen City. 90 patients in group A were treated with Atto vastatin calcium tablets (20 mg / g QD) and group B were treated with rosuvastatin calcium tablets (10 mg / g QD). The course of treatment was 8 weeks. The level of blood lipid index, the effect of lowering blood lipid, the rate of blood lipid reaching standard and the occurrence of adverse reaction were compared between the two groups before and after treatment, and the economic evaluation was carried out by cost-effect analysis method. Results: before treatment, there was no significant difference in blood lipid levels between the two groups (P0.05). After treatment, the levels of total cholesterol and low density lipoprotein cholesterol in both groups were significantly lower than those before treatment, and the levels in group B were significantly lower than those in group A. The total effective rate (97.78%) of group B was significantly higher than that of group A (86.67%), and the rate of blood lipid reaching standard (66.67%) was significantly higher than that of group A (51.11%), the difference was statistically significant (P0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P0.05). The cost of group A and group B was 488.32436.24 yuan, respectively. The cost-effect ratio was 5.63% 4.46, and the incremental cost-effect ratio was -4.69%. Sensitivity analysis supports cost-effect analysis results. Conclusion: compared with that of 20 mg/d Atto vastatin regimen, rosuvastatin regimen for 10 mg/d is more effective and cost effective, and its safety is similar.
【作者单位】：天门市第一人民医院药剂科;武汉大学人民医院心血管内科;
【基金】：国家自然科学基金资助项目(No.81370365)
【分类号】：R589.2

【相似文献】